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Both griseofulvin (11, 16, 17) and Methotrexate
(6a) are capable of arresting mitosis of certain
cells in metaphase. Both griseofulvin (18) and
Methotrexate (23), when administered orally,
will reach the skin. It had previously been re-
ported that griseofulvin exerted an antitumor
action when mice are placed on a griseofulvin
diet of 10 to 15 mgm/Kgm/day either at the
start of or 2 weeks prior to epidermal applica-
tions of the carcinogenic agent, methylcholan-
threne (1, 3). However, griseofulvin exerted a
co-carcinogenic action when mice were placed on
this same diet 6 weeks prior to epidermal applica-
tions of methylcholanthrene (4). These mice
experiments with prolonged administration of
griseofulvin converting an anti-tumor effect into
a cocarcinogenic effect on methylcholanthrene-
induced epidermal tumors stimulated the follow-
ing research with Methotrexate.
MATERIAL AND METHODS
Male white Swiss mice from Maxfield Animal
Supply in Cincinnati, weighing 18 to 20 Grams at
the start of experimentation were used. 3-Methyl-
cholanthrene was obtained from the Mann Re-
search Laboratories. Methotrexate (Amethop-
term) was supplied by J. Frank Hurdle, M.D. of
Lederle Laboratories. Rockland Rat Diet pro-
duced by E. Staley Manufacturing Company of
Decatur, Illinois was used as the basic food.
Methotrexate was incorporated into the powdered
food so that mice on this drug would receive a
dosage of approximately 0.2 mgm/Kgm/day, the
exact amount depending upon size and food intake.
Group A initially consisted of 46 mice that re-
ceived only the regular food devoid of any Metho-
trexate.
Group B initially consisted of 29 mice that were
placed on the Methotrexate diet, 6 weeks prior,
during and subsequent to methylcholanthrene
applications.
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Group C initially consisted of 15 mice that were
placed on the Methotrexate diet one week prior,
during and subsequent to methyicholanthrene
applications.
All 3 groups received biweekly applications of
0.04 cc. of 0.5% methylcholanthrene in acetone for
11 weeks to the shaved epidermis of the intra-
scapular area. The mice were then checked almost
daily for tumor latent period, number of tumors
per mouse and the percentage of mice developing
tumors per group.
RESULTS
Tumor inventories of selected days are pre-
sented in Table I and Figure 1. Initially, the
tumors appeared as red pinpoint papillomas.
These may then grow until they reach a diameter
of as large as 40 mm. and a height of 15 mm. Often
numerous small papillomas will form a large
confluent tumorous mass with subsequent de-
creased individual number of tumors. Occasion-
ally, a tumor was bitten off or regressed in size
and thus was not present for a continuously
increasing tumor inventory with the passage of
time. As the tumors enlarged ulcerated and/or
necrotic areas developed. Previous histological
study showed that given sufficient time, some of
the methyleholanthrene-induced papillomas de-
veloped into squamous cell carcinomas (2).
Table I and Figure 1 show that Methotrexate
exerted the anticipated antitumor effect when
given for 1 week prior, during and subsequent to
methylcholanthrene applications to the epidermis
of mice. Group C had a delay in the tumor latent
period and a much lower percentage of mice
developed tumors than mice in Group A. Table
I and Figure 1 also show that prolonged adminis-
tration of Methotrexate for 6 weeks prior, during
and subsequent to methylcholanthrene applica-
tions resulted in a marked co-carcinogenic effect.
Group B had a shortened tumor latent period
and a much higher percentage of mice developed
tumors than mice in Group A.
DISCUSSION
Thus, there were parallel findings between
griseofulvin and Methotrexate, suggesting that
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TABLE I
Influence of oral methoirexate on methyicholanthrene-induced cutaneous mouse tumors
Days after
start of
methlcho-
lanthrene
Group A Group B Group C
C tumors
of mice °
Total
Tumors
S C tumors
5 of mice e
Total
Tumors
S e tumors
s of mice
Total
Tumors
20
30
45
56
82
91
101
112
0/46
1/46
0/46
2/46
18/42
26/41
26/40
29/39
0
2.2
0
4.4
42.9
63.4
65.0
74.4
0
1
0
2
45
89
139
159
1/29
4/28
7/28
8/28
25/28
25/28
26/28
26/27
3.4
14.3
25.0
28.5
89.5
89.5
93.0
96.3
1
4
7
8
75
121
115
138
0/15
0/14
1/14
1/14
2/14
3/14
3/14
5/14
0
0
7.25
7.25
14.3
21.4
21.4
35.7
0
0
1
1
3
7
7
18
Group A. On regular food throughout experiment
Group B. On Methotrexate diet for 6 weeks prior, during and subsequent to methyicholanthrene
application
Group C. On Methotrexate diet for 1 week prior, during and subsequent to methyicholanthrene
application
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prolonged administration can convert an anti-
tumor action into a cocarcinogenic action.
Methotrexate (Amethopterin) is well known as
the rare cancer chemotherapeutic drug that has
resulted in cancer "cures" in patients with chorio-
epitheliomas (9, 12, 15). Van Scott (23) has used
Methotrexate with some degree of success in the
treatment of skin cancer.
The proper dose and type of x-ray will have an
anti-tumor effect on certain skin cancers. But
with prolonged cutaneous administration of x-ray
a carcinogenic effect can be exerted resulting in
the formation of squamous cell carcinomas
(19, 25). Arsenic has been used in the treatment
of chronic myelogenous leukemia with a marked
drop in the white blood cell count after adminis-
tration (6b). Prolonged administration of arsenic
(as in the therapy of psoriasis or pemphigus)
may result in a carcinogenic effect, with the
formation of squamous cell cancers and Bowen's
disease with associated visceral malignancies
(7). Estrogenic substances are useful in the treat-
ment of prostatic cancer but can intensify the
growth of ovarian and breast tumors (6c). It has
recently been shown that prolonged administra-
tion of stilbesterol in mice has a cocarcinogenie
effect on methylcholanthrene induced epidermal
tumors (21). Urethane has been used in the
treatment of leukemia and in multiple myeloma
(6d). It has recently been shown that prolonged
administration of oral urethane has a marked
multipotential carcinogenic effect in the Syrian
hamster (22).
In the conference on the comparative clinical
and biological effects of alkylating agents of the
N. Y. Academy of Sciences, Stock and Sugiura
(20) discussed the tumor inhibiting effects of
alkylating agents and Walpole (24) discussed the
carcinogenic action of alkylating agents. Under
one set of experimental conditions alkylating
agents such as triethylene melamine (TEM),
Myleran and the nitrogen mustards possessed
an antitumor action (20) but under another
set of experimental conditions a carcinogenic
action resulted, when a prolonged waiting period
was involved (24).
The experiments with griseofulvin and Metho-
trexate show that prolonged administration can
convert an antitumor effect into a co-carcinogenic
effect in methylcholanthrene induced cutaneous
tumors in mice. These experiments and a brief
review of related literature suggest the working
hypothesis that at least under the proper experi-
mental conditions, prolonged administration of
certain substances which affects mitosis can con-
vert an anti-tumor effect into a coearcinogenic
effect and at times a carcinogenic effect. More
experiments are needed with the specific obj cc-
tives of testing this possible hypothesis.
These experiments raise many questions re-
garding cancer ehemotherapeutie drugs. Can the
cancer cell with a much more complicated chemi-
cal and enzymatic system than a bacterium,
convert its metabolic processes from sensitivity
to a drug to resistance and perhaps utilization
of the drug in its metabolic processes. This would
be similar to bacterial resistance to a drug to
which it was previously sensitive. To what extent
can a drug with antimitotie effect disturb the
mitosis of a cancer cell or its progeny before there
is resistance to it? Would our cancer cure rate
with cancer ehemotherapeutic drugs be higher
if used in combinations or rotated frequently so
that different metabolic pathways are attacked
in the cancer cell before resistance is developed?
Malkinson (8, 14) at at. have reported that there
is increased responsiveness to x-ray irradiation
following intravenous administration of colehicine
in a patient with mycosis fungoides. Epstein (5)
has shown that griseofulvin can potentiate
eolchicine toxicity in mice. ilosley (10) has shown
that Amethopterin, 5-fluorouracil or Actinomycin
D given simultaneously with radiation can
materially reduce tumors in patients with ad-
vanced lung cancer but without distant metas-
tasis as compared with radiation alone. Loken
(13) at a!. have shown that the combined therapy
of irradiation and folie acid antagonists is more
effective in the treatment of mouse mammary
carcinomas than x-ray alone. Can or will chemical
or other tests have to be devised to determine
when prolonged administration of a cancer
ehemotherapeutic drug is having its antitumor
effect converted into a tumor promoting effect?
To what extent will future screening tests for
toxicity of drugs have to take into consideration
changes at the cellular as well as the organ level?
Many patients with nonmalignant cutaneous
diseases receive drugs which affect mitosis. These
patients may be heavy cigarette smokers or
farmers or sailors with excessive exposure to the
sun or chemical petroleum workers exposed to
carcinogens. Does such a patient with psoriasis
receiving Aminopterin or Methotrexate for
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prolonged periods of time or a patient with ony-
chomycosis receiving griseofulvin for prolonged
periods of time increase his chance of developing
a malignancy? These are only some of the cur-
rently unanswerable questions stimulated by
this research.
SUMMARY
Methotrexate administered orally for one week
prior, during and subsequent to methylcholan-
threnc applications to the epidermis of mice
exerted (the anticipated) anti-tumor effect. How-
ever, when administered orally in the same dosage
for six weeks prior, during and subsequent to
methylcholanthrene applications, there was a
marked co-carcinogenic effect. More tumors
developed per mouse, they appeared earlier, and
in a larger percentage of mice than in the con-
trols treated similarly with methylcholanthrene
but without receiving Methotrexate. These ex-
periments parallel our findings with griseofulvin
and suggest that prolonged administration may
convert an anti-tumor agent into a co-carcinogen.
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